Drug industry’s Covid-19 push didn’t cross over to other viruses

In reporting on the 2021 Access to Medicine Index, Naomi Kresge for Bloomberg focuses on the total lack of research on 10 of 16 emerging infectious diseases identified as potential pandemic risks.

Naomi underlines that the 20 pharmaceutical companies analysed by the 2021 Index have little motivation towards developing health products for low-income countries. This is in stark contrast to the actions of the industry against COVID-19 where she identifies an "unprecedented response".

The article further stresses the spike in research into coronaviruses which leaves other emerging infectious diseases behind.

Read the full article here.